This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients

This study has been terminated.
(Lack of patients to enroll.)
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Korea Inc. ) Identifier:
First received: September 12, 2005
Last updated: November 19, 2013
Last verified: November 2013
This study investigate the relationship between regional brain volume measured by MRI and donepezil treatment response in patients with Alzheimer's Disease.

Condition Intervention Phase
Alzheimer's Disease Drug: DONEPEZIL HYDROCHLORIDE Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients

Resource links provided by NLM:

Further study details as provided by Eisai Inc. ( Eisai Korea Inc. ):

Primary Outcome Measures:
  • MRI, ADAS-cog [ Time Frame: 0, 12, 24 weeks ]

Secondary Outcome Measures:
  • ADL, BPSD, CDR-SB, ZBI, GHQ, CIBIC plus [ Time Frame: 0, 12, 24 weeks ]

Enrollment: 40
Study Start Date: March 2005
Study Completion Date: November 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
Other Name: Aricept


Ages Eligible for Study:   60 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  1. Over 60 years old.
  2. Probable or possible Alzheimer's Disease according to the DSM-IV and NINCDS-ADRDA.
  3. MMSE score of 10~24, CDR of 1~2.
  4. Patients didn't take acetylcholinesterase inhibitors 4 weeks before screening.
  5. Permitted drugs: antipsychiatric drug for BPSD, antidepression drug, tranquilizer, treatment drug for physical disease for example hypertension.

Exclusion criteria:

  1. Uncontrolled by donepezil because of adverse events.
  2. No longer continuing treatment of donepezil for refuse, drug-drug interaction etc.
  3. If they have taken concomitant medication which were not allowed.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00165750

Korea, Republic of
Cheonnam University Hospital
Gwangju, Korea, Republic of
Sponsors and Collaborators
Eisai Korea Inc.
Study Director: Jihee Mun Eisai Korea Inc.
  More Information

Responsible Party: Eisai Korea Inc. Identifier: NCT00165750     History of Changes
Other Study ID Numbers: AS-019 (EKI-5-003)
Study First Received: September 12, 2005
Last Updated: November 19, 2013

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents processed this record on September 19, 2017